Европейски съюз - български - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - Други лекарства противоанемические - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

Европейски съюз - български - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - Антинеопластични средства - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Европейски съюз - български - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - азацитидин - Левкемия, миелоиден, остър - Антинеопластични средства - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Европейски съюз - български - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - Антинеопластични средства - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Европейски съюз - български - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - Антинеопластични средства - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Европейски съюз - български - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - Меланомът - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Европейски съюз - български - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - Гликогенна складова болест тип ii - Други стомашно-чревния тракт и обмяната на веществата средства, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Европейски съюз - български - EMA (European Medicines Agency)

pfizer europe ma eeig - бозутиниб (като монохидрат) - Левкемия, миелоид - antineoplastic agents, protein kinase inhibitors - bosulif е показан за лечение на възрастни пациенти с идентифицирана за първи път хронична фаза (cp) на хромозомите-положителен Филаделфия хронична миелогенной левкемия (ph+ ХМЛ). СР, ускорена фаза (ap), и бластном (bp) ph+ ХМЛ, по-рано, на които един или повече инхибитори на тирозинкиназы(с) [tgc(И)] и за кого imatinib, nilotinib и dasatinib не се считат за подходящи възможности за лечение .

Европейски съюз - български - EMA (European Medicines Agency)

pfizer europe ma eeig - варениклин - Прекратяване употребата на тютюн - Други лекарства в нервната система - champix е показан за спиране на тютюнопушенето при възрастни.